Medical/Pharmaceuticals
50% ORR: Impressive Clinical Trial Data for Irpagratinib Combined with Atezolizumab in Advanced Hepatocellular Carcinoma Stuns ESMO-GI Congress
SHANGHAI, June 27, 2024 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (Abbisko Therapeutics) announced that it has presented new phase II clinical data of its highly selective FGFR4 inhibitor irpagratinib (ABSK011) in combination with atezolizumab for the treatment of advanced hepatocellular carc...
2024-06-28 10:30
2873
Harbour BioMed Announces Resubmission of Biologics License Application for Batoclimab to NMPA for Treatment of Generalized Myasthenia Gravis
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, June 26, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunol...
2024-06-27 07:08
3133
The Future of Telehealth Relies on Seamless UC&C Monitoring
* IR launches a healthcare bundle to meet the demands of proactive communication monitoring in healthcare organizations. SYDNEY, June 26, 2024 /PRNewswire/ -- IR (ASX:IRI), a leading provider of global performance management and analytics for Unified Communications and Collaboration (UC&C), h...
2024-06-26 21:30
3546
bioSeedin Expanded Global Licensing and Partnership Opportunities at 2024 BIO International Convention
NEWARK, Del., June 26, 2024 /PRNewswire/ -- bioSeedin, a flourishing global licensing and consulting platform, captivated attendees as an esteemed exhibitor at the BIO International Convention, the preeminent global biotech gathering. This prestigious event unfolded inSan Diego, spanning from Jun...
2024-06-26 21:00
2341
Neurophet to present brain stimulation simulation study at OHBM 2024
- Presents a poster identifying tDCS effects for patients with AD and cognitively normal people - Showcases brain imaging treatment planning software for electric brain stimulation Neurophet tESplan Plus SEOUL, South Korea, June 26, 2024 /PRNewswire/ -- Neurophet, an artificial intelligence (AI...
2024-06-26 21:00
3049
Positive Xanamem® biomarker trial published in the Journal of Alzheimer's Disease demonstrating potential Xanamem efficacy in patients with elevated blood pTau
The prospectively defined, double-blind analysis of biomarker-positive patients with mild Alzheimer's disease showed more rapid clinical progression in biomarker-positive patients, highlighting the suitability of elevated pTau for selecting patients in the on-going XanaMIA phase2b trial SYDNEY, ...
2024-06-26 20:56
3343
Fufang E'jiao Syrup's Breakthrough Research on Cancer-Related Fatigue Receives "Special Excellence Award" at 2024 ASCO Annual Meeting
CHICAGO, June 26, 2024 /PRNewswire/ -- The 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO), a significant event in the global oncology community, was grandly held inChicago, USA, from May 31 to June 4, 2024. ASCO has announced the list of outstanding abstracts for 2024, wh...
2024-06-26 18:42
2280
Simcere Zaiming Announce Approval of Cetuximab Beta in China by the NMPA
NANJING, China, June 26, 2024 /PRNewswire/ -- On June 25, 2024, Simcere Zaiming, an innovative oncology company and a subsidiary of Simcere Pharmaceutical Group (2096.HK), announced that Enlituo® (generic name: cetuximab beta injection), a new generation anti-epidermal growth factor receptor (EG...
2024-06-26 12:36
3016
Hyundai Bioscience succeeds in developing 'Multi-treatment for mosquito-borne viral infections' including Dengue Fever
* Developed a 'Niclosamide-based multi-treatment drug' that can simultaneously treat mosquito-borne viral infections such as four serotypes of dengue virus, Zika, Chikungunya, and Yellow Fever. * Accelerating preparations for dengue fever basket clinical trial scheduled to be conducted inBraz...
2024-06-26 09:17
3065
ONO PHARMA USA Announces Support for Conquer Cancer®, the ASCO Foundation
Conquer Cancer Supports Cancer Research and Education CAMBRIDGE, Mass., June 25, 2024 /PRNewswire/ -- ONO PHARMA USA today announced it will provide a sponsorship to Conquer Cancer®, the ASCO Foundation, with$1 million funding to advance cancer research and education. Conquer Cancer is a glob...
2024-06-25 21:00
2188
Porton Advanced introduces the MaxCyte ExPERT GTx Flow Electroporation instrument, continuing to provide customers with end-to-end cell and gene therapy CRO & CDMO services
SUZHOU, China, June 25, 2024 /PRNewswire/ -- Porton Advanced recently introduced the MaxCyte cGMP-grade ExPERT GTx Flow Electroporation instrument to its cell therapy platform, marking the company as the first cell therapy CDMO in China to possess this clinical-grade flow electroporation system. T...
2024-06-25 20:00
3189
NX Group Signs Strategic Partnership Agreement with Controlant of Iceland
- Set to Provide Real-time Monitoring Service for Tracking Cargo Location and Strict Temperature Control - TOKYO, June 25, 2024 /PRNewswire/ -- NIPPON EXPRESS HOLDINGS, INC. has signed a strategic partnership agreement withIceland-based Controlant, Inc., a leading provider of real-time monitorin...
2024-06-25 14:00
2371
TiumBio Presents Promising Clinical Data from Phase 1 of its Hemophilia Treatment Candidate TU7710 at ISTH 2024
* TU7710, long-acting recombinant activated factor VII, demonstrated a 5 to 7 times longer half-lifein a Phase 1 study than that of NovoSeven, a conventional hemophilia treatment for patients who develop inhibitors * TiumBio presented interim Phase 1a clinical data of TU7710 and discussed pot...
2024-06-24 20:00
2933
iRegene Receives IND approval from U.S. FDA to Start Clinical Trial for Parkinson's Disease
WUHAN, China, June 24, 2024 /PRNewswire/ -- On June 20 (UTC-4), the U.S. Food and Drug Administration (FDA) approved the IND application for NouvNeu001, a cell therapy product from iRegene therapeutics targeting Parkinson's Disease. This marks a significant milestone as NouvNeu001 becomes the wor...
2024-06-24 20:00
2645
Wingderm® Shines at IMCAS Asia 2024 with the Innovative Aesthetic Solutions
BEIJING, June 24, 2024 /PRNewswire/ -- From June 21 to 23, IMCAS Asia was held
inBangkok, Thailand. Wingderm®, a provider of medical aesthetic devices, has
garnered significant attention with its innovative aesthetic solutions.
2024-06-24 12:31
3672
Keymed Biosciences Announces Safety and Efficacy Results of CM313 for Primary Immune Thrombocytopenia Published in NEJM
CHENGDU, China, June 20, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced that Lei Zhang/Renchi Yang's team from the Institute of Hematology, Chinese Academy of Medical Sciences has recently published a research paper entitled "A Novel Anti-CD38 Monoclonal Antibody for T...
2024-06-20 14:51
2508
GC Cell Signs an MOU with PT Bifarma Adiluhung, an affiliate of KALBE group
* GC Cell and PT Bifarma Adiluhung announced a strategic partnership to
facilitate the entry of 'Immuncell-LC', the only approved autologous T-cell
therapy for HCC into the Indonesian market. YONGIN, South Korea, June 19, 2024
/PRNewswire/ --GC Cell
2024-06-20 08:44
4176
SINBON and MAKALOT partner to drive cross-industry textile wearable adoption
SAN FRANCISCO, June 19, 2024 /PRNewswire/ -- Digital technology is playing a transformative role in our everyday life, shaping not only how we interact with the world around us but also ourselves. The impact of this trend is most prevalent when examining the wellness landscape, where consumers co...
2024-06-20 00:00
3684
CMT Research Foundation Invests in ReviR Therapeutics Research to Pioneer Small Molecule Therapeutics for CMT1A
ATLANTA, June 19, 2024 /PRNewswire/ -- The CMT Research Foundation, a non-profit focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease (CMT)*, has formed a strategic partnership with ReviR Therapeutics to advance small molecule therapeutics that modulate the expressio...
2024-06-19 21:00
3676
Golidocitinib Approved in China as First-in-class JAK1 Only Inhibitor for the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma
* Golidocitinib is a first-in-class Janus kinase 1 (JAK1) only inhibitor approved for the treatment of r/r PTCL based on results from the multinational pivotal JACKPOT8B study. * Golidocitinib monotherapy demonstrated superior and durable clinical benefits and a favorable safety profile in r/...
2024-06-19 19:30
3287
Week's Top Stories
Most Reposted
Agoda Begins Limited Public Beta of New AI Assistant That Turns Travel Ideas into Bookable Trips
[Picked up by 289 media titles]
2026-09-15 11:00
Avnet and The University of Hong Kong Open EMUS Lab to Accelerate AI Innovation and Commercialization in Hong Kong
[Picked up by 281 media titles]
2026-09-17 13:09
Sovereign Investment Institutions Launch China-ASEAN Joint Investment Council
[Picked up by 267 media titles]
2026-09-16 09:09
USSEC Advances Aquaculture Feed Formulation in Asia
[Picked up by 264 media titles]
2026-09-17 09:00
CLP Power Hosts AESIEAP CEO Conference 2026 in Hong Kong
[Picked up by 260 media titles]
2026-09-15 19:07
Most Read
ALLSWIFIT Introduces ActiveRise+, a Stable Carbon-Plate Running Shoe Built to Help Everyday Runners Train Smarter and Run Stronger
2026-09-11 21:00
14673
Cheetah Mobile Announces Second Quarter 2026 Unaudited Consolidated Financial Results
2026-09-11 10:36
10841
